Zacks Investment Research upgraded shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) from a sell rating to a hold rating in a report issued on Wednesday.
According to Zacks, “AMAG reported earnings of $1.57 in the third quarter of 2017 as against the Zacks Consensus Estimate of a loss. However, the company missed the same on revenues. AMAG lowered its total revenue guidance for 2017. Furthermore, the termination of the licensing agreement with Takeda for Feraheme in ex-U.S. territories was a major setback for the company. So far this year, AMAG’s shares have underperformed the industry. Nevertheless, the company is working towards label expansion of Feraheme, and potential approval and launch of the Makena subcutaneous auto-injector (SQ) AMAG also remains focused on expanding Makena’s label further in a bid to increase its market share.”
AMAG has been the topic of several other reports. Jefferies Group LLC restated a buy rating and set a $16.00 price target on shares of AMAG Pharmaceuticals in a report on Sunday, November 5th. ValuEngine upgraded shares of AMAG Pharmaceuticals from a strong sell rating to a sell rating in a report on Tuesday, July 25th. Piper Jaffray Companies began coverage on shares of AMAG Pharmaceuticals in a report on Monday, October 23rd. They set a neutral rating and a $18.00 price target on the stock. BidaskClub cut shares of AMAG Pharmaceuticals from a buy rating to a hold rating in a report on Thursday, August 10th. Finally, Deutsche Bank AG reiterated a hold rating and issued a $24.00 price objective on shares of AMAG Pharmaceuticals in a report on Thursday, August 31st. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and three have issued a buy rating to the company’s stock. AMAG Pharmaceuticals presently has a consensus rating of Hold and a consensus price target of $24.00.
AMAG Pharmaceuticals (NASDAQ:AMAG) traded down $0.15 during trading on Wednesday, hitting $14.05. 763,600 shares of the stock traded hands, compared to its average volume of 1,126,475. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59. AMAG Pharmaceuticals has a fifty-two week low of $11.93 and a fifty-two week high of $36.83.
COPYRIGHT VIOLATION WARNING: This news story was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://stocknewstimes.com/2017/11/11/amag-pharmaceuticals-inc-amag-upgraded-at-zacks-investment-research.html.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Schroder Investment Management Group raised its position in shares of AMAG Pharmaceuticals by 101.2% during the third quarter. Schroder Investment Management Group now owns 83,945 shares of the specialty pharmaceutical company’s stock valued at $1,490,000 after buying an additional 42,233 shares during the last quarter. Trexquant Investment LP acquired a new position in shares of AMAG Pharmaceuticals during the third quarter valued at about $412,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of AMAG Pharmaceuticals during the third quarter valued at about $342,000. Macquarie Group Ltd. bought a new stake in AMAG Pharmaceuticals in the third quarter valued at about $266,000. Finally, 361 Capital LLC bought a new stake in AMAG Pharmaceuticals in the third quarter valued at about $197,000.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.